Physician-scored and patient-reported bowel toxicity higher with dose-escalated moderately hypofractionated radiotherapy<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, April 1, 2025 (HealthDay News) — For patients with prostate cancer, isodose and dose-escalated moderately hypofractionated radiotherapy (MHFRT) have similar efficacy as conventionally fractionated radiotherapy (CFRT), but bowel toxicity is seen in association with dose-escalated MHFRT, according to a study published online March 17 in The Lancet Oncology<\/em>.<\/p>\n Amar U. Kishan, M.D., from the University of California, Los Angeles, and colleagues conducted an individual patient data meta-analysis from randomized phase 3 trials of CFRT versus MHFRT for prostate cancer. Seven phase 3 trials were eligible for inclusion; data were obtained for 3,454 patients from three trials comparing CFRT to isodose MHFRT and 2,426 patients from four trials comparing CFRT to dose-escalated MHFRT.<\/p>\n The researchers found no differences in progression-free survival at a median follow-up of 5.4 years for isodose MHFRT and 7.1 years for dose-escalated MHFRT. For isodose and dose-escalated MHFRT, there were no increased odds of grade 2 or higher genitourinary toxic effects. With dose-escalated, but not isodose MHFRT, the odds of grade 2 or higher gastrointestinal toxic effects were significantly greater (odds ratio, 1.48). Odds of urinary quality-of-life decrement or bowel quality-of-life decrement were no different for isodose MHFRT. Greater odds of bowel quality-of-life decrement were seen with dose-escalated MHFRT (odds ratio, 1.68), but no greater urinary quality-of-life decrement was seen.<\/p>\n “This meta-analysis provides the strongest evidence to date suggesting an isodose MHFRT regimen could be the preferred MHFRT regimen for all risk groups,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n